What is Kodiak Sciences?
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical firm dedicated to the research, development, and commercialization of innovative treatments for retinal diseases. The company's lead candidate, tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer, is currently undergoing advanced clinical trials for wet age-related macular degeneration (AMD) and other serious retinal conditions including diabetic macular edema and non-proliferative diabetic retinopathy. Kodiak Sciences also has preclinical assets, such as KSI-501, a bispecific conjugate targeting IL-6 and VEGF, and KSI-101, a protein targeting the same pathways for retinal inflammatory conditions. Originally founded as Oligasis, LLC in 2009 and based in Palo Alto, California, the company rebranded to Kodiak Sciences Inc. in September 2015.
How much funding has Kodiak Sciences raised?
Kodiak Sciences has raised a total of $476.4M across 6 funding rounds:
Other Financing Round
$1.8M
Series B
$34M
Debt
$33M
Stock Offering
$90M
Stock Offering
$317.4M
Debt
$150K
Other Financing Round (2009): $1.8M with participation from Undisclosed
Series B (2016): $34M led by Undisclosed
Debt (2018): $33M supported by Perceptive Advisors and ArrowMark Partners
Stock Issuance/Offering (2018): $90M featuring Undisclosed
Stock Issuance/Offering (2019): $317.4M backed by Undisclosed
Debt (2020): $150K with participation from PPP
Key Investors in Kodiak Sciences
Perceptive Advisors
Perceptive Advisors, established in 1999 and headquartered in New York, is an investment firm managing approximately $7 billion in assets. The firm specializes in funding cutting-edge healthcare and life sciences technologies, aligning with Kodiak Sciences' focus on biopharmaceutical innovation.
ArrowMark Partners
ArrowMark Partners is an investment entity that has participated in funding rounds for Kodiak Sciences. Further details on their specific investment focus within the life sciences sector are not immediately available but their involvement suggests a strategic interest in the company's therapeutic development.
Undisclosed Investors
What's next for Kodiak Sciences?
The significant enterprise-level funding Kodia Sciences has attracted indicates a strong investor confidence in its pipeline and strategic direction. This capital infusion is expected to accelerate the clinical development of its lead product candidate, tarcocimab tedromer, through its late-stage trials and support the advancement of its preclinical assets. The company's focus on addressing unmet needs in retinal diseases positions it for potential market leadership, with future growth likely driven by successful regulatory approvals and commercialization efforts.
See full Kodiak Sciences company page
